Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Kantarjian, HM' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 154 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Ferrajoli, A; Manshouri, T; Estrov, Z; Keating, MJ; O'Brien, S; Lerner, S; Beran, M; Kantarjian, HM; Freireich, EJ; Albitar, M
      High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia

      CLINICAL CANCER RESEARCH
    2. Aboul-Nasr, R; O'Brien, S; Freireich, EJ; Ginsberg, CF; Kantarjian, HM; Koller, CA; Keating, MJ; Albitar, M
      "T-cell-rich B-cell lymphoproliferative disorder" of the bone marrow

      LEUKEMIA & LYMPHOMA
    3. Dabaja, BS; O'Brien, SM; Kantarjian, HM; Cortes, JE; Thomas, DA; Albitar, M; Schlette, ES; Faderl, S; Sarris, A; Keating, MJ; Giles, FJ
      Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoxome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome

      LEUKEMIA & LYMPHOMA
    4. Giles, FJ; Shen, Y; Kantarjian, HM; Korbling, MJ; O'Brien, S; Anderlini, P; Donato, M; Pierce, S; Keating, MJ; Freireich, EJ; Estey, E
      Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long term survival

      LEUKEMIA & LYMPHOMA
    5. Fleming, RV; Kantarjian, HM; Husni, R; Rolston, K; Lim, J; Raad, I; Pierce, S; Cortes, J; Estey, E
      Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia

      LEUKEMIA & LYMPHOMA
    6. Thomas, DA; Kantarjian, HM
      The revitalization of thalidomide

      ANNALS OF ONCOLOGY
    7. Thomas, DA; Kantarjian, HM
      Lymphoblastic lymphoma

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    8. Kantarjian, HM; Hoelzer, D; Larson, RA
      Advances in the treatment of adult acute lymphocytic leukemia, part II - Preface

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    9. Kantarjian, HM
      Adult acute lymphocytic leukemia - Future research directions

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    10. Giles, FJ; Cortes, JE; Baker, SD; Thomas, DA; O'Brien, S; Smith, TL; Beran, M; Bivins, C; Jolivet, J; Kantarjian, HM
      Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    11. Albitar, M; Manshouri, T; Gidel, C; Croce, C; Kornblau, S; Pierce, S; Kantarjian, HM
      Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia

      LEUKEMIA RESEARCH
    12. Faderl, S; Gidel, C; Kantarjian, HM; Manshouri, T; Keating, M; Albitar, M
      Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia

      LEUKEMIA RESEARCH
    13. Kantarjian, HM; Talpaz, M; Santini, V; Murgo, A; Cheson, B; O'Brien, SM
      Homoharringtonine - History, current research, and future directions

      CANCER
    14. Giles, FJ; Kantarjian, HM; Kornblau, SM; Thomas, DA; Garcia-Manero, G; Waddelow, TA; David, CL; Phan, AT; Colburn, DE; Rashid, A; Estey, EH
      Mylotarg(TM) (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

      CANCER
    15. Kantarjian, HM; Shan, JQ; Smith, T; Talpaz, M; Kozuch, P; Rios, MB; Cortes, J; Giles, FJ; O'Brien, S
      Response to therapy is independently associated with survival prolongationin chronic myelogenous leukemia in the blastic phase

      CANCER
    16. Ravandi, F; Hayes, K; Cortes, J; Albitar, M; Glassman, A; Talpaz, M; Kantarjian, HM
      Translocation t(17;18)(q10;q10) - A new nonrandom chromosomal translocation of clonal evolution in chronic myeloid leukemia

      CANCER
    17. Ravandi, F; Kantarjian, HM; Talpaz, M; O'Brien, S; Faderl, S; Giles, FJ; Thomas, D; Cortes, J; Andreeff, M; Estrov, Z; Rios, MB; Albitar, M
      Expression of apoptosis proteins in chronic myelogenous leukemia - Associations and significance

      CANCER
    18. Talpaz, M; O'Brien, S; Rose, E; Gupta, S; Shan, JQ; Cortes, J; Giles, FJ; Faderl, S; Kantarjian, HM
      Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia

      BLOOD
    19. Estey, EH; Thall, PF; Cortes, JE; Giles, FJ; O'Brien, S; Pierce, SA; Wang, XM; Kantarjian, HM; Beran, M
      Comparison of idarubicin plus ara-C-, fludarabine plus ara-C-, and topotecan plus ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

      BLOOD
    20. Ibrahim, S; Keating, M; Do, KA; O'Brien, S; Huh, YO; Jilani, I; Lerner, S; Kantarjian, HM; Albitar, M
      CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

      BLOOD
    21. Santini, V; Kantarjian, HM; Issa, JP
      Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications

      ANNALS OF INTERNAL MEDICINE
    22. Molldrem, JJ; Lee, PP; Wang, CQ; Felio, K; Kantarjian, HM; Champlin, RE; Davis, MM
      Evidence that specific T lymphocytes may participate in the elimination ofchronic myelogenous leukemia

      NATURE MEDICINE
    23. Reuben, JM; Lee, BN; Johnson, H; Fritsche, H; Kantarjian, HM; Talpaz, M
      Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha

      CLINICAL CANCER RESEARCH
    24. Tannir, NM; Talpaz, M; Ghazal, H; Proothi, S; Kantarjian, HM
      Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    25. Romaguera, JE; Khouri, IF; Kantarjian, HM; Hagemeister, FB; Rodriguez, MA; McLaughlin, P; Sarris, AH; Younes, A; Rodriguez, J; Cabanillas, F
      Untreated aggressive mantle cell lymphoma: Results with intensive chemotherapy without stem cell transplant in elderly patients

      LEUKEMIA & LYMPHOMA
    26. Saad, ED; Thomas, DA; O'Brien, S; Fuller, GN; Medeiros, LJ; Forman, A; Albitar, M; Schomer, D; Kantarjian, HM; Keating, MJ
      Progressive multifocal leukoencephalopathy with concurrent Richter's syndrome

      LEUKEMIA & LYMPHOMA
    27. Huh, YO; Smith, TL; Collins, P; Bueso-Ramos, C; Albitar, M; Kantarjian, HM; Pierce, SA; Freireich, EJ
      Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometry

      LEUKEMIA & LYMPHOMA
    28. Giles, FJ; Wong, GC; Clark, SJ; Pierce, S; Kantarjian, HM; Keating, MJ
      Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    29. Faderl, S; Kantarjian, HM; Thomas, DA; Cortes, J; Giles, F; Pierce, S; Albitar, M; Estrov, Z
      Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

      LEUKEMIA & LYMPHOMA
    30. Thomas, DA; Kantarjian, HM
      Current role of thalidomide in cancer treatment

      CURRENT OPINION IN ONCOLOGY
    31. Faderl, S; Kantarjian, HM; Talpaz, M; Estrov, Z
      Clinical significance of minimal residual disease in leukemia (Review)

      INTERNATIONAL JOURNAL OF ONCOLOGY
    32. Haidar, MA; Manshouri, T; Keating, MJ; Kantarjian, HM; Freireich, EJ; Mehta, K; Albitar, M
      Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice

      INTERNATIONAL JOURNAL OF ONCOLOGY
    33. Kantarjian, HM
      Adult acute lymphocytic leukemia - Introduction and questions related to current programs

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    34. Garcia-Manero, G; Kantarjian, HM
      The hyper-CVAD regimen in adult acute lymphocytic leukema

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    35. Kantarjian, HM; Hoelzer, D; Larson, RA
      Advances in the treatment of adult acute lymphocytic leukemia, part I - Preface

      HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
    36. Kantarjian, HM; O'Brien, S; Smith, TL; Cortes, J; Giles, FJ; Beran, M; Pierce, S; Huh, Y; Andreeff, M; Koller, C; Ha, CS; Keating, MJ; Murphy, S; Freireich, EJ
      Results of treatment with Hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    37. Kantarjian, HM; Talpaz, M; Smith, TL; Cortes, J; Giles, FJ; Rios, MB; Mallard, S; Gajewski, A; Murgo, A; Cheson, B; O'Brien, S
      Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    38. Cortes, J; Kantarjian, HM
      Promising approaches in acute leukemia

      INVESTIGATIONAL NEW DRUGS
    39. Faderl, S; Kantarjian, HM; Talpaz, M; O'Brien, S
      New treatment approaches for chronic myelogenous leukemia

      SEMINARS IN ONCOLOGY
    40. Faderl, S; Kantarjian, HM; Estey, E; Manshouri, T; Chan, CY; Elsaied, AR; Kornblau, SM; Cortes, J; Thomas, DA; Pierce, S; Keating, MJ; Estrov, Z; Albitar, M
      The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia

      CANCER
    41. Kantarjian, HM; Giles, FJ; O'Brien, S
      Therapeutic choices in younger patients with chronic myelogenous leukemia

      CANCER
    42. Farhad, R; Cortes, J; Albitar, M; Arlinghaus, R; Guo, JQ; Talpaz, M; Kantarjian, HM
      Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance (vol 107, pg 581, 1999)

      BRITISH JOURNAL OF HAEMATOLOGY
    43. Ibrahim, S; Estey, EH; Pierce, S; Glassman, A; Keating, M; O'Brien, S; Kantarjian, HM; Albitar, M
      11q23 Abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses

      AJCP. American journal of clinical pathology
    44. Faderl, S; Estrov, Z; Kantarjian, HM; Thomas, D; Cortes, J; Manshouri, T; Chan, CC; Hays, KJ; Pierce, S; Albitar, M
      The incidence of chromosome 9p21 abnormalities and deletions of tumor suppressor genes p15(INK4b)/p16(INK4a)/p14(ARF) in patients with acute lymphoblastic leukemia

      CYTOKINES CELLULAR & MOLECULAR THERAPY
    45. Faderl, S; Kantarjian, HM; Manshouri, T; Chan, CY; Pierce, S; Hays, KJ; Cortes, J; Thomas, D; Estrov, Z; Albitar, M
      The prognostic significance of p16(INK4a)/p14(ARF) and p15(INK4b) deletions in adult acute lymphoblastic leukemia

      CLINICAL CANCER RESEARCH
    46. Faderl, S; Thall, PF; Kantarjian, HM; Talpaz, M; Harris, D; Van, Q; Beran, M; Kornblau, SM; Pierce, S; Estrov, Z
      Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia

      CLINICAL CANCER RESEARCH
    47. Kantarjian, HM; Talpaz, M; O'Brien, S; Manshouri, T; Cortes, J; Giles, F; Rios, MB; Croce, CM; Albitar, M
      Significance of FHIT expression in chronic myelogenous leukemia

      CLINICAL CANCER RESEARCH
    48. Giles, FJ; O'Brien, SM; Santini, V; Gandhi, V; Plunkett, W; Seymour, JF; Robertson, LE; Kantarjian, HM; Keating, MJ
      Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study

      LEUKEMIA & LYMPHOMA
    49. Sacchi, S; Kantarjian, HM; Freireich, EJ; O'Brien, SO; Cortes, J; Rios, MB; Kornblau, S; Giles, FJ; Koller, C; Gajewski, J; Talpaz, M
      Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia

      LEUKEMIA & LYMPHOMA
    50. Wilhelm, M; O'Brien, S; Rios, MB; Estey, E; Keating, MJ; Plunkett, W; Sorenson, M; Kantarjian, HM
      Phase I study of arabinosyl-5-azacytidine (Fazarabine) in adult acute leukemia and chronic myelogenous leukemia in elastic phase

      LEUKEMIA & LYMPHOMA
    51. Seong, D; Kantarjian, HM; Albitar, M; Arlinghaus, R; Xu, J; Talpaz, M; Rios, MB; Guo, JQ; O'Brien, S; Siciliano, M
      Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization

      ANNALS OF ONCOLOGY
    52. Faderl, S; Kantarjian, HM; Talpaz, M
      Chronic myelogenous leukemia: Update on biology and treatment

      ONCOLOGY-NEW YORK
    53. Dabaja, BS; Faderl, S; Thomas, D; Cortes, J; O'Brien, S; Nasr, F; Pierce, S; Hayes, K; Glassman, A; Keating, M; Kantarjian, HM
      Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications

      LEUKEMIA
    54. Kantarjian, HM; O'Brien, S; Smith, TL; Rios, MB; Cortes, J; Beran, M; Koller, C; Giles, FJ; Andreeff, M; Kornblau, S; Giralt, S; Keating, MJ; Talpaz, M
      Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

      JOURNAL OF CLINICAL ONCOLOGY
    55. Faderl, S; Talpaz, M; Estrov, Z; O'Brien, S; Kurzrock, R; Kantarjian, HM
      Mechanisms of disease - The biology of chronic myeloid leukemia

      NEW ENGLAND JOURNAL OF MEDICINE
    56. Giles, FJ; Kantarjian, HM; Cortes, J; Thomas, DA; Talpaz, M; Manshouri, T; Albitar, M
      Multidrug resistance protein expression in chronic myeloid leukemia - Associations and significance

      CANCER
    57. Sacchi, S; Kantarjian, HM; O'Brien, S; Cortes, J; Rios, MB; Giles, FJ; Beran, M; Koller, CA; Keating, MJ; Talpaz, M
      Chronic myelogenous leukemia in nonlymphoid blastic phase - Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients

      CANCER
    58. Koller, CA; Kantarjian, HM; Feldman, EJ; O'Brien, S; Rios, MB; Estey, E; Keating, M
      A Phase I-II trial of escalating doses of mitoxantrone with fixed doses ofcytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia

      CANCER
    59. Cortes, JE; Kantarjian, HM; O'Brien, S; Giles, F; Keating, MJ; Freireich, EJ; Estey, EH
      A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission

      CANCER
    60. Ravandi-Kashani, F; Cortes, J; Talpaz, M; Kantarjian, HM
      Thrombotic microangiopathy associated with interferon therapy for patientswith chronic myelogenous leukemia - Coincidence or true side effect?

      CANCER
    61. Aguayo, A; Cortes, JE; Kantarjian, HM; Beran, M; Gandhi, V; Plunkett, W; Kurtzberg, J; Keating, MJ
      Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogeneous leukemia in T-cell blastic phase - A case report and review of the literature

      CANCER
    62. Ravandi, F; Cortes, J; Albitar, M; Arlinghaus, R; Guo, JQ; Talpaz, M; Kantarjian, HM
      Chronic myelogenous leukaemia with p185(BCR/ABL) expression: characteristics and clinical significance

      BRITISH JOURNAL OF HAEMATOLOGY
    63. Estrov, Z; Manna, SK; Harris, D; Van, Q; Estey, EH; Kantarjian, HM; Talpaz, M; Aggarwal, BB
      Phenylarsine oxide blocks interleukin-1 beta-induced activation of the nuclear transcription factor NF-kappa B, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells

      BLOOD
    64. Silver, RT; Woolf, SH; Hehlmann, R; Appelbaum, FR; Anderson, J; Bennett, C; Goldman, JM; Guilhot, F; Kantarjian, HM; Lichtin, AE; Talpaz, M; Tura, S
      An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

      BLOOD
    65. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction and clinical decision making - Response

      BLOOD
    66. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Polymerase chain reaction analyses should be used as a basis for clinical decision making in patients with chronic myelogenous leukemia - Response

      BLOOD
    67. Faderl, S; Talpaz, M; Kantarjian, HM; Estrov, Z
      Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?

      BLOOD
    68. Faderl, S; Talpaz, M; Estrov, Z; Kantarjian, HM
      Chronic myelogenous leukemia: Biology and therapy

      ANNALS OF INTERNAL MEDICINE
    69. Weinkauff, R; Estey, EH; Starostik, P; Hayes, K; Huh, YO; Hirsch-Ginsberg, C; Andreeff, M; Keating, M; Kantarjian, HM; Freireich, EJ; Albitar, M
      Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia

      AJCP. American journal of clinical pathology
    70. Aboul-Nasr, R; Estey, EH; Kantarjian, HM; Freireich, EJ; Andreeff, M; Johnson, BJ; Albitar, M
      Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens

      AJCP. American journal of clinical pathology
    71. SEONG D; THALL P; KANTARJIAN HM; TALPAZ M; SWANTKOWSKI J; XU JP; SHEN Y; GLASSMAN A; RAMAGLI L; SICILIANO MJ
      PHILADELPHIA-CHROMOSOME-POSITIVE MYELOID CELLS IN THE PERIPHERAL-BLOOD OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS - COMPARISON WITH THE FREQUENCY DETECTED IN CYCLING CELLS OF THE BONE-MARROW

      Clinical cancer research
    72. SEONG D; THALL P; KANTARJIAN HM; TALPAZ M; SWANTKOWSKI J; XU JP; SHEN Y; GLASSMAN A; RAMAGLI L; SICILIANO MJ
      PHILADELPHIA-CHROMOSOME-POSITIVE MYELOID CELLS IN THE PERIPHERAL-BLOOD OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS - COMPARISON WITH THE FREQUENCY DETECTED IN CYCLING CELLS OF THE BONE-MARROW

      Clinical cancer research
    73. Beran, M; Estey, E; O'Brien, SM; Giles, FJ; Koller, CA; Kornblau, S; Keating, M; Kantarjian, HM
      Results of topotecan single-agent therapy in patients with myelodysplasticsyndromes and chronic myelomonocytic leukemia

      LEUKEMIA & LYMPHOMA
    74. KANTARJIAN HM; GILES FJ; OBRIEN SM; TALPAZ M
      CLINICAL COURSE AND THERAPY OF CHRONIC MYELOGENOUS LEUKEMIA WITH INTERFERON-ALPHA AND CHEMOTHERAPY

      Hematology/oncology clinics of North America
    75. SCHENK TM; KEYHANI A; BOTTCHER S; KLICHE KO; GOODACRE A; GUO JQ; ARLINGHAUS RB; KANTARJIAN HM; ANDREEFF M
      MULTILINEAGE INVOLVEMENT OF PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA

      Leukemia
    76. WILHELM M; BUESORAMOS C; OBRIEN S; PIERCE S; KEATING M; TALPAZ M; KANTARJIAN HM
      EFFECT OF INTERFERON-ALPHA THERAPY ON BONE-MARROW FIBROSIS IN CHRONICMYELOGENOUS LEUKEMIA

      Leukemia
    77. SACCHI S; KANTARJIAN HM; SMITH TL; OBRIEN S; PIERCE S; KORNBLAU S; BERAN M; KEATING MJ; TALPAZ M
      EARLY TREATMENT DECISIONS WITH INTERFERON-ALPHA THERAPY IN EARLY CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    78. ESTROV Z; THALL PF; TALPAZ M; ESTEY EH; KANTARJIAN HM; ANDREEFF M; HARRIS D; VAN Q; WALTERSCHEID M; KORNBLAU SM
      CASPASE-2 AND CASPASE-3 PROTEIN-LEVELS AS PREDICTORS OF SURVIVAL IN ACUTE MYELOGENOUS LEUKEMIA

      Blood
    79. KANTARJIAN HM; TALPAZ M
      QUESTIONS RAISED BY THE BENELUX CML STUDY-GROUP - RESULTS FROM THE RANDOMIZED STUDY WITH HYDROXYUREA ALONE VERSUS HYDROXYUREA COMBINED WITHLOW-DOSE INTERFERON-ALPHA-2B FOR CHRONIC MYELOID-LEUKEMIA

      Blood
    80. FADERL S; KANTARJIAN HM; TALPAZ M; ESTROV Z
      CLINICAL-SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA

      Blood
    81. KANTARJIAN HM; TALPAZ M; OBRIEN S; KURZROCK R; GUTTERMAN J; KEATING MJ; MCCREDIE KB; FREIREICH EJ
      CHRONIC MYELOGENOUS LEUKEMIA - PROGRESS AT THE M.-D.-ANDERSON-CANCER-CENTER OVER THE PAST 2 DECADES AND FUTURE-DIRECTIONS - FIRST FREIREICH,EMIL,J AWARD LECTURE

      Clinical cancer research
    82. CORTES J; KANTARJIAN HM; GIRALT S; TALPAZ M
      NATURAL-HISTORY AND STAGING OF CHRONIC MYELOGENOUS LEUKEMIA

      Bailliere's clinical haematology
    83. TALPAZ M; KANTARJIAN HM; OBRIEN S; KURZROCK R
      THE M.D.-ANDERSON-CANCER-CENTER EXPERIENCE WITH INTERFERON-ALPHA THERAPY IN CHRONIC MYELOGENOUS LEUKEMIA

      Bailliere's clinical haematology
    84. BSEISO AW; KANTARJIAN HM; GUO JQ; CORTES J; TALPAZ M; KOLLER C; ALBITAR M; KEATING M; ARLINGHAUS R
      ANALYSIS OF THE BCR-ABL PROTEIN IN PHILADELPHIA-CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOCYTIC-LEUKEMIA

      Leukemia
    85. KOLLER CA; KANTARJIAN HM; THOMAS D; OBRIEN S; RIOS MB; KORNBLAU S; MURPHY S; KEATING M
      THE HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA

      Leukemia
    86. SACCHI S; KANTARJIAN HM; OBRIEN S; BERAN M; KOLLER C; PIERCE S; KORNBLAU S; ESTEY E; KEATING MJ; TALPAZ M
      LONG-TERM FOLLOW-UP RESULTS OF ALPHA-INTERFERON-BASED REGIMENS IN PATIENTS WITH LATE CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    87. KANTARJIAN HM; OBRIEN SM; KEATING M; BERAN M; ESTEY E; GIRALT S; KORNBLAU S; RIOS MB; DEVOS D; TALPAZ M
      RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    88. KANTARJIAN HM
      THE ROLE OF DECITABINE IN HEMATOLOGIC MALIGNANCIES

      Leukemia
    89. KANTARJIAN HM; OBRIEN SM; ESTEY E; GIRALT S; BERAN M; RIOS MB; KEATING M; DEVOS D; TALPAZ M
      DECITABINE STUDIES IN CHRONIC AND ACUTE MYELOGENOUS LEUKEMIA

      Leukemia
    90. BOUVET M; BABIERA GV; TERMUHLEN PM; HESTER JP; KANTARJIAN HM; POLLOCK RE
      SPLENECTOMY IN THE ACCELERATED OR BLASTIC PHASE OF CHRONIC MYELOGENOUS LEUKEMIA - A SINGLE-INSTITUTION, 25-YEAR EXPERIENCE

      Surgery
    91. RODRIGUEZMONGE EJ; CORTES JE; OBRIEN S; TALPAZ M; KANTARJIAN HM
      THIOTEPA FOR THE TREATMENT OF THROMBOCYTHEMIA IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

      Cancer
    92. KOLLER CA; KANTARJIAN HM; THOMAS D; OBRIEN S; RIOS MB; KORNBLAU S; MURPHY S; KEATING M
      HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA

      Blood
    93. GHADDAR HM; PIERCE S; KANTARJIAN HM; FREIREICH EJ; KEATING MJ; ESTEY EH
      AMSACRINE AND CONTINUOUS-INFUSION HIGH-DOSE CYTOSINE-ARABINOSIDE AS INDUCTION THERAPY FOR PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA

      Leukemia & lymphoma
    94. ESCUDIER SM; KANTARJIAN HM; ESTEY EH
      THROMBOSIS IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA TREATED WITHAND WITHOUT ALL-TRANS-RETINOIC ACID

      Leukemia & lymphoma
    95. ANDERLINI P; GHADDAR HM; SMITH TL; PIERCE S; KANTARJIAN HM; OBRIEN S; KEATING MJ; FREIREICH EJ; ESTEY EH
      FACTORS PREDICTING COMPLETE REMISSION AND SUBSEQUENT DISEASE-FREE SURVIVAL AFTER A 2ND COURSE OF INDUCTION THERAPY IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA RESISTANT TO THE FIRST

      Leukemia
    96. ANDERLINI P; LUNA M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; ESTEY EH
      CAUSES OF INITIAL REMISSION INDUCTION FAILURE IN PATIENTS WITH ACUTE MYELOID-LEUKEMIA AND MYELODYSPLASTIC SYNDROMES

      Leukemia
    97. KANTARJIAN HM; BERAN M; OBRIEN S; ROBERTSON L; SIDDIK Z; YOSHIDA M; YANG LY; RIOS MB; KEATING MJ; MEYER M; KOWAL C; ESTEY EH
      EVALUATION OF CL-973, A PLATINUM ANALOG, IN REFRACTORY OR RELAPSED ACUTE-LEUKEMIA

      Leukemia
    98. ESCUDIER SM; ALBITAR M; ROBERTSON LE; ANDREEFF M; PIERCE S; KANTARJIAN HM
      ACUTE LYMPHOBLASTIC-LEUKEMIA FOLLOWING PRELEUKEMIC SYNDROMES IN ADULTS

      Leukemia
    99. WILHELM M; KANTARJIAN HM; OBRIEN S; PIERCE S; KEATING MJ; FREIREICH EJ; ESTEY EH
      PNEUMONIA DURING REMISSION INDUCTION CHEMOTHERAPY IN PATIENTS WITH AML OR MDS

      Leukemia
    100. KORNBLAU SM; GANDHI V; ANDREEFF HM; BERAN M; KANTARJIAN HM; KOLLER CA; OBRIEN S; PLUNKETT W; ESTEY E
      CLINICAL AND LABORATORY STUDIES OF 2-CHLORODEOXYADENOSINE+ -CYTOSINE-ARABINOSIDE FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA IN ADULTS/

      Leukemia


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/05/20 alle ore 12:53:17